Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Revitol Cellulite Cream

AMSA Celebrates 50th Medical Student Conference In Brisbane
The 2009 Australian Medical Students" Association (AMSA) Convention begins on Monday with 850 future doctors joining leaders in health and politics to debate the hot issues in healthcare. Don't forget to buy zoloft online no prescription.

Prospective Clinical Advantages Of Trabecular Metal(TM) Technology Highlighted In Comparative Study
Zimmer Holdings, Inc. (NYSE: ZMH; SWX: ZMH) announced that data from a comparative clinical study conducted by researchers at the Mayo Clinic and the Joint Replacement Surgeons of the Indiana Research Foundation describes the low stiffness and osteoconductive properties of Zimmer"s Trabecular Metal Technology. The study, published in The Journal of Arthroplasty, found significant reductions in acetabular bone loss adjacent to the Trabecular Metal device compared to the titanium component, and a significant relative increase in bone mineral density (BMD) after total hip arthroplasty (THA) using implants made with Zimmer"s proprietary Trabecular Metal Technology.

generic viagra online


News of the day
StemCells, Inc. To Present Phase I Clinical Trial Results At The 12th International Congress On NCL
StemCells, Inc. (NASDAQ:STEM) announced plans to present data from its Phase I clinical trial of its proprietary HuCNS-SC® product candidate (purified human neural stem cells) at the 12th International Congress on Neuronal Ceroid Lipofuscinoses (NCL) being held June 3 - 6, 2009 in Hamburg, Germany. Stephen Huhn, MD, FACS, FAAP, vice president and head of the Company"s CNS program, is scheduled to present the data on Saturday, June 6.
Cardiovascular

Total Artificial Heart Bridges People Rejecting Donor Hearts To 2nd Transplant

During 2008, 10% of people who were implanted with the SynCardia temporary CardioWest™ Total Artificial Heart received the device because they were suffering from rejection of their donor heart transplant. Jim Hennigan, 44, received his first heart transplant in 2004 but suffered from rejection of the new heart. In July 2008, doctors implanted Hennigan with the Total Artificial Heart and bridged him to a second heart transplant 310 days later. "The Total Artificial Heart did a phenomenal job of keeping me healthy and active for more than 10 months," said Hennigan, who was transplanted on May 8, 2009. "As a matter of fact, the Total Artificial Heart was so efficient that my body is still trying to adapt to my new "run of the mill" human heart." Implantation of the Total Artificial Heart is similar to a heart transplant in that it replaces both heart ventricles, eliminating biventricular heart failure. However, unlike a donor heart, the Total Artificial Heart has no risk of rejection because it is made of biocompatible materials. "For someone suffering from donor heart rejection, surgical implantation of any other device will increase the risk of infection because the patient is still taking immunosuppressant drugs for their donor heart," said Richard Smith, MSEE, CCE, Director of the Artificial Heart Program at University Medical Center and Chief Technical Officer for SynCardia. "The Total Artificial Heart is the only device that replaces the donor heart and eliminates the need for immunosuppressant drugs." SynCardia Total Artificial Heart


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009